Values shown are regression estimates, with shaded areas indicating 95% CIs. Nephrotic Syndrome Rare Disease Clinical Research Network (NEPTUNE) included 166 participants, with 1827 observations; focal segmental glomerulosclerosis clinical trial (FSGS-CT) included 132 participants, with 1992 observations; Kidney Research Network (KRN) included 184 participants, with 3082 observations. The pooled analysis included 482 participants, with 6901 observations.